Santen Pharmaceutical Co., Ltd. SZD.F Stock
Santen Pharmaceutical Co., Ltd. Price Chart
Santen Pharmaceutical Co., Ltd. SZD.F Financial and Trading Overview
Santen Pharmaceutical Co., Ltd. stock price | 8.75 EUR |
Previous Close | 7.65 EUR |
Open | 7.75 EUR |
Bid | 7.7 EUR x 100000 |
Ask | 8.15 EUR x 100000 |
Day's Range | 7.75 - 7.75 EUR |
52 Week Range | 6.4 - 8.6 EUR |
Volume | 200 EUR |
Avg. Volume | 15 EUR |
Market Cap | 2.99B EUR |
Beta (5Y Monthly) | 0.344444 |
PE Ratio (TTM) | N/A |
EPS (TTM) | 0.45 EUR |
Forward Dividend & Yield | 0.22 (2.70%) |
Ex-Dividend Date | September 28, 2023 |
1y Target Est | N/A |
SZD.F Valuation Measures
Enterprise Value | -56430780416 EUR |
Trailing P/E | N/A |
Forward P/E | 10.064936 |
PEG Ratio (5 yr expected) | 297.02 |
Price/Sales (ttm) | 0.010702053 |
Price/Book (mrq) | 0.009900168 |
Enterprise Value/Revenue | -0.202 |
Enterprise Value/EBITDA | -3.986 |
Trading Information
Santen Pharmaceutical Co., Ltd. Stock Price History
Beta (5Y Monthly) | 0.344444 |
52-Week Change | 13.86% |
S&P500 52-Week Change | 20.43% |
52 Week High | 8.6 EUR |
52 Week Low | 6.4 EUR |
50-Day Moving Average | 7.78 EUR |
200-Day Moving Average | 7.25 EUR |
SZD.F Share Statistics
Avg. Volume (3 month) | 15 EUR |
Avg. Daily Volume (10-Days) | 0 EUR |
Shares Outstanding | 375.58M |
Float | 367.97M |
Short Ratio | N/A |
% Held by Insiders | 3.31% |
% Held by Institutions | 58.62% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 32 |
Trailing Annual Dividend Yield | 418.30% |
5 Year Average Dividend Yield | 200.00% |
Payout Ratio | N/A |
Last Split Factor | 5:1 |
Financial Highlights
Fiscal Year
Fiscal Year Ends | March 31, 2023 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | March 31, 2024 |
Profitability
Profit Margin | -5.35% |
Operating Margin (ttm) | -1.10% |
Gross Margin | 59.52% |
EBITDA Margin | 5.07% |
Management Effectiveness
Return on Assets (ttm) | -0.43% |
Return on Equity (ttm) | -4.75% |
Income Statement
Revenue (ttm) | 279.04B EUR |
Revenue Per Share (ttm) | 720.24 EUR |
Quarterly Revenue Growth (yoy) | 12.50% |
Gross Profit (ttm) | N/A |
EBITDA | 14.16B EUR |
Net Income Avi to Common (ttm) | -14954999808 EUR |
Diluted EPS (ttm) | -0.14 |
Quarterly Earnings Growth (yoy) | -85.79% |
Balance Sheet
Total Cash (mrq) | 58.68B EUR |
Total Cash Per Share (mrq) | 156.25 EUR |
Total Debt (mrq) | 0 EUR |
Total Debt/Equity (mrq) | N/A |
Current Ratio (mrq) | 2.383 |
Book Value Per Share (mrq) | 782.815 |
Cash Flow Statement
Operating Cash Flow (ttm) | 37.15B EUR |
Levered Free Cash Flow (ttm) | -12089124864 EUR |
Profile of Santen Pharmaceutical Co., Ltd.
Country | Germany |
State | N/A |
City | Osaka |
Address | Grand Front Osaka Tower A |
ZIP | 530-8552 |
Phone | 81 6 7664 8621 |
Website | https://www.santen.com |
Industry | Drug Manufacturers-General |
Sector(s) | Healthcare |
Full Time Employees | N/A |
Santen Pharmaceutical Co., Ltd. researches and develops, manufactures, and markets pharmaceuticals and medical devices in Japan and internationally. It offers various pharmaceutical products, including Verkazia, which is used for the treatment of vernal keratoconjunctivitis; STN1008903, which is used for dry eye treatment; Eybelis for the treatment of glaucoma and ocular hypertension; Alesion, an anti-allergy ophthalmic solution; Diquas for the treatment for dry eye syndrome; and glaucoma products, such as Tapros, Tapcom, PRESERFLO MicroShunt, and ROCK inhibitor products. The company also developing various pharmaceutical products to treat glaucoma, such as STN1014000, which is in clinical preparation; STN1012600, which is in Phase II clinical trial; STN1011101, STN1013001, and STN1013900, which are in Phase III clinical trial; STN1011402, which is in Phase III clinical trial to treat allergies; STN1010904, which is in Phase II clinical trial to treat fuchs endothelial corneal dystrophy; STN1010905, which is in Phase II clinical trial to treat meibomian gland dysfunction; and STN1013600, which is in Phase I clinical trial to treat presbyopia. In addition, it provides STN1012701, which is in Phase III clinical trial to treat myopia; STN1013800, which is in clinical preparation to treat ptosis; STN6000100, which is in clinical preparation to treat retinitis pigmentosa; STN1013400, which is in Phase I clinical trial to treat myopia; and STN1012700, which is in Phase I clinical trial to treat myopia. Further, it offers over-the-counter pharmaceutical products. The company was formerly known as Santendo Pharmaceutical Co., Ltd. and changed its name to Santen Pharmaceutical Co., Ltd. in 1958. Santen Pharmaceutical Co., Ltd. was founded in 1890 and is headquartered in Osaka, Japan.
Q&A For Santen Pharmaceutical Co., Ltd. Stock
What is a current SZD.F stock price?
Santen Pharmaceutical Co., Ltd. SZD.F stock price today per share is 8.75 EUR.
How to purchase Santen Pharmaceutical Co., Ltd. stock?
You can buy SZD.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Santen Pharmaceutical Co., Ltd.?
The stock symbol or ticker of Santen Pharmaceutical Co., Ltd. is SZD.F.
Which industry does the Santen Pharmaceutical Co., Ltd. company belong to?
The Santen Pharmaceutical Co., Ltd. industry is Drug Manufacturers-General.
How many shares does Santen Pharmaceutical Co., Ltd. have in circulation?
The max supply of Santen Pharmaceutical Co., Ltd. shares is 367.58M.
What is Santen Pharmaceutical Co., Ltd. Price to Earnings Ratio (PE Ratio)?
Santen Pharmaceutical Co., Ltd. PE Ratio is 19.44444500 now.
What was Santen Pharmaceutical Co., Ltd. earnings per share over the trailing 12 months (TTM)?
Santen Pharmaceutical Co., Ltd. EPS is 0.45 EUR over the trailing 12 months.
Which sector does the Santen Pharmaceutical Co., Ltd. company belong to?
The Santen Pharmaceutical Co., Ltd. sector is Healthcare.